Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Medical Oncology
Do you use maintenance bevacizumab in addition to immunotherapy after 1st line chemotherapy + immunotherapy + bevacizumab in metastatic cervical squamous cell carcinoma?
Related Questions
What are your top takeaways from SGO 2025?
What are your top takeaways in Gyn Cancers from ASCO 2025?
Between KEYNOTE A-18 and INTERLACE, for which patients would you recommend using one protocol over another?
What is your approach to IV fluid management for the treatment of hypercalcemia of malignancy?
What screening tools or signs do you use to predict if a cancer patient is near end-of-life?
Would you consider adding immunotherapy to adjuvant chemotherapy in a patient with incompletely staged, high-grade, MSI-H, POLE-mutated endometrioid carcinoma of the ovary with ultra-high tumor mutation burden on NGS?
In patients treated with the KEYNOTE A-18 regimen who later recur, would you rechallenge with immunotherapy again?
For an elderly woman with a platinum-resistant recurrence of a high-grade serous ovarian cancer who has been rendered NED surgically, is observation a reasonable approach?
How do you counsel patients about prognosis with FIGO 2018 IIIC cervix cancer managed in the new era of chemoradiation plus immunotherapy?
How have you incorporated ctDNA into the clinical management of patients with gynecologic cancers?
